Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 2.14 is 19% below its 5-year average of 2.63, near the low end of its 5-year range (2.13–3.44).
As of the fiscal period ended Tuesday, June 30, 2026. 15.49% below its 12-month average of 2.53.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 2.14.
QUICK RATIO (ACID-TEST)
2.14
QUICK RATIO (ACID-TEST) AVG TTM
2.53
QUICK RATIO (ACID-TEST) AVG 3Y
2.76
QUICK RATIO (ACID-TEST) AVG 5Y
2.63
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-15.49%
CURRENT VS 3Y AVG
-22.52%
CURRENT VS 5Y AVG
-18.69%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
-36.21%
vs the sector median at left
Market Cap
$2.03B
Quick Ratio (Acid-Test)
0.96
TTM Avg
0.99
3Y Avg
1.34
5Y Avg
1.34
Market Cap
$2.03B
Quick Ratio (Acid-Test)
3.41
TTM Avg
4.73
3Y Avg
4.98
5Y Avg
5.02
Market Cap
$2.03B
Quick Ratio (Acid-Test)
2.29
TTM Avg
2.30
3Y Avg
3.09
5Y Avg
3.45
Market Cap
$2.02B
Quick Ratio (Acid-Test)
4.97
TTM Avg
4.46
3Y Avg
5.74
5Y Avg
7.97
Market Cap
$2.06B
Quick Ratio (Acid-Test)
16.95
TTM Avg
14.04
3Y Avg
14.82
5Y Avg
14.35
Market Cap
$2.06B
Quick Ratio (Acid-Test)
4.69
TTM Avg
4.29
3Y Avg
4.33
5Y Avg
4.67
Market Cap
$2.07B
Quick Ratio (Acid-Test)
11.82
TTM Avg
14.70
3Y Avg
15.08
5Y Avg
16.52
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Progyny, Inc. (PGNY) | $2.03B | 2.14 | 2.53 | 2.76 | 2.63 |
| Fortrea Holdings Inc. (FTRE)vs › | $2.03B | 0.96 | 0.99 | 1.34 | 1.34 |
| UroGen Pharma Ltd. (URGN)vs › | $2.03B | 3.41 | 4.73 | 4.98 | 5.02 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.03B | 2.29 | 2.30 | 3.09 | 3.45 |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 4.97 | 4.46 | 5.74 | 7.97 |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | 16.95 | 14.04 | 14.82 | 14.35 |
| Vericel Corporation (VCEL)vs › | $2.06B | 4.69 | 4.29 | 4.33 | 4.67 |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | 11.82 | 14.70 | 15.08 | 16.52 |
| Alvotech (ALVO)vs › | $2.08B | 0.96 | 1.42 | 1.06 | 1.08 |
| Vera Therapeutics, Inc. (VERA)vs › | $2.08B | 10.92 | 19.66 | 12.98 | 14.20 |
Quick Ratio
2.14
Excludes inventory
Current Ratio
2.14
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 2.14 |
| 2026-03-31 | 2.13 |
| 2025-12-31 | 2.73 |
| 2025-09-30 | 2.96 |
| 2025-06-30 | 2.70 |
| 2025-03-31 | 2.39 |
| 2024-12-31 | 2.80 |
| 2024-09-30 | 2.62 |
| 2024-06-30 | 2.58 |
| 2024-03-31 | 3.31 |
| 2023-12-31 | 3.44 |
| 2023-09-30 | 3.16 |
| 2023-06-30 | 2.89 |
| 2023-03-31 | 2.55 |
| 2022-12-31 | 2.72 |
| 2022-09-30 | 2.56 |
| 2022-06-30 | 2.46 |
| 2022-03-31 | 2.40 |
| 2021-12-31 | 2.62 |
| 2021-09-30 | 2.44 |
| 2021-06-30 | 2.41 |
| 2021-03-31 | 2.26 |
| 2020-12-31 | 2.45 |
| 2020-09-30 | 2.49 |
| 2020-06-30 | 2.77 |
| 2020-03-31 | 2.74 |
| 2019-12-31 | 3.66 |
| 2019-09-30 | 0.93 |
| 2019-06-30 | 1.13 |
| 2019-03-31 | 0.95 |
| 2018-12-31 | 0.81 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
